Search

Your search keyword '"Pierrick Poisbeau"' showing total 2 results
Start Over Author "Pierrick Poisbeau" Journal plos one
2 results on '"Pierrick Poisbeau"'

1. The non-benzodiazepine anxiolytic etifoxine limits mechanical allodynia and anxiety-like symptoms in a mouse model of streptozotocin-induced diabetic neuropathy

Author

Géraldine Gazzo, Marlene Salgado Ferrer, and Pierrick Poisbeau

Subjects
Medicine, Science
Abstract

More than 450 million people worldwide suffer from diabetes, or 1 in 11 people. Chronic hyperglycemia degrades patients’ quality of life and the development of neuropathic pain contributes to the burden of this disease. In this study, we used the mouse model of streptozocin-induced diabetic type 1 neuropathy to assess the analgesic potential of etifoxine. Etifoxine is a prescribed anxiolytic that increases GABAAA receptor function through a direct positive allosteric modulation effect and, indirectly, by stimulating the production of endogenous GABAA receptor positive modulators such as allopregnanolone-type neurosteroids. We show that a post-symptomatic or preventive treatment strongly and durably reduces mechanical hyperalgesia and anxiety in diabetic neuropathic mice. This analgesic and neuroprotective effect on painful symptoms and emotional comorbidities is promising and should now be clinically evaluated.

Published
2021

2. The non-benzodiazepine anxiolytic etifoxine limits mechanical allodynia and anxiety-like symptoms in a mouse model of streptozotocin-induced diabetic neuropathy

Author

Marlene Salgado Ferrer, Géraldine Gazzo, Pierrick Poisbeau, Institut des Neurosciences Cellulaires et Intégratives (INCI), and Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Diabetic neuropathy, Anxiety, Pharmacology, Biochemistry, Mice, Endocrinology, Medical Conditions, 0302 clinical medicine, Diabetic Neuropathies, Medicine and Health Sciences, Medicine, Energy-Producing Organelles, Pain Measurement, Analgesics, 0303 health sciences, Multidisciplinary, GABAA receptor, Drugs, Mitochondria, 3. Good health, Allodynia, Neurology, Hyperalgesia, Neuropathic pain, Cellular Structures and Organelles, medicine.symptom, Research Article, medicine.drug, Neuroactive steroid, Endocrine Disorders, medicine.drug_class, Science, Pain, Bioenergetics, Anxiolytic, Diabetes Mellitus, Experimental, 03 medical and health sciences, Signs and Symptoms, Diabetes mellitus, Oxazines, Diabetes Mellitus, Pain Management, Animals, GABA-A Receptor Agonists, Neuropathic Pain, 030304 developmental biology, business.industry, Biology and Life Sciences, Cell Biology, medicine.disease, Neuropathy, Mice, Inbred C57BL, Etifoxine, Anti-Anxiety Agents, Metabolic Disorders, Clinical Medicine, business, Open Field Test, Anxiolytics, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract

More than 450 million people worldwide suffer from diabetes, or 1 in 11 people. Chronic hyperglycemia degrades patients’ quality of life and the development of neuropathic pain contributes to the burden of this disease. In this study, we used the mouse model of streptozocin-induced diabetic type 1 neuropathy to assess the analgesic potential of etifoxine. Etifoxine is a prescribed anxiolytic that increases GABAAA receptor function through a direct positive allosteric modulation effect and, indirectly, by stimulating the production of endogenous GABAA receptor positive modulators such as allopregnanolone-type neurosteroids. We show that a post-symptomatic or preventive treatment strongly and durably reduces mechanical hyperalgesia and anxiety in diabetic neuropathic mice. This analgesic and neuroprotective effect on painful symptoms and emotional comorbidities is promising and should now be clinically evaluated.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results